SAN DIEGO, June 15, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology announced today that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT886, its anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal […]
SAN DIEGO, April 20, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, revealed that the company has completed the manufacturing scale production of a bispecific antibody constructed with its PACbody™ and SPECpair™ technologies. The details were presented in one of its posters at this year’s American Association […]
SAN DIEGO, April 12, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, announced today that the company has been granted a patent (Patent No. US 11,299,550 B2) on its anti-CD73 antibodies by the United States Patent and Trademark Office (USPTO). The patent includes the invention of PT199, […]
SAN DIEGO, March 22, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in immuno-oncology announced today that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT199, its next generation monoclonal antibody (mAb) against CD73 in adult patients with advanced solid […]
SAN DIEGO, March 16, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology, announced today that three posters featuring its IND-enabling stage molecules will be presented at the upcoming 2022 American Association for Cancer Research (AACR 2022) Annual Meeting, which will be held April 8-13, 2022, in New Orleans, LA. […]
SAN DIEGO, Feb. 4, 2022 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and development in immuno-oncology announced today that the company has been granted a patent (Patent No. US11,214,615) by the United States Patent and Trademark Office (USPTO). Phanes has been focusing on innovative drug discovery and early development in immuno-oncology and […]
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has appointed Mr. Paul Chu, MBA, as Vice President of Business Development. “We welcome Paul to the Phanes family and are delighted to appoint a professional of his caliber as Vice President of Business Development,” […]
SAN DIEGO, Dec. 15, 2021 /PRNewswire/ — Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery and development in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2022, to be held January 10–12, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Ming Wang, CEO, […]
SAN DIEGO, Sept. 10, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third […]
SAN DIEGO and SHANGHAI, May 25, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology, announced today the completion of $40 million Series B financing. The round of financing was led by Sequoia Capital China with participation from new investors and current shareholders. The proceeds from this round will be […]
